Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Black Diamond Therapeutics, Inc.BDTX · Entity 6669 | Director | June 26, 2026 | June 29, 2026 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director | May 26, 2026 | May 27, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Black Diamond Therapeutics, Inc.
Report date June 26, 2026 · Filed June 29, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.71 · Expires 2036-06-25 | Direct | 40,000 |
Reported balance
After 2026-06-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-06-26 · Grant · Acquired 40,000 · Balance 40,000 F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date.
Zentalis Pharmaceuticals, Inc.
Report date May 26, 2026 · Filed May 27, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 114,200 |
Reported balance
After 2026-05-26 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-26 · Grant · Acquired 114,200 · Balance 114,200 F1: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 26, 2026 Filed Jun 29, 2026 20:32 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $1.71 | $0.00 |
DisclosureSEC source: 0002018966-26-000007 · form4-06292026_080653.xml · derivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2036-06-25 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 26, 2027 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| May 26, 2026 Filed May 27, 2026 20:11 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 114,200 | $0.00 | $0.00 |
DisclosureSEC source: 0002018966-26-000005 · wk-form4_1779912686.xml · nonDerivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 114,200 F1 · balance_after: The restricted stock units ("RSUs") were granted by the Issuer pursuant to the Issuer's Non-Employee Director Compensation Program. One third of the RSUs will vest on each of the first, second and third anniversaries of the grant date, subject to the reporting person's continued service with the Issuer on each vesting date. Read SEC document |
| June 12, 2025 Filed Jun 12, 2025 22:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 30,550 | $0.00 Strike: $2.43 | $0.00 |
DisclosureSEC source: 0001415889-25-017053 · form4-06122025_100629.xml · derivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 30,550 shares Expires 2035-06-11 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2026 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| December 13, 2024 Filed Dec 16, 2024 21:34 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 4,500 | $2.50 | $11,250.00 |
DisclosureSEC source: 0001415889-24-029481 · form4-12162024_091212.xml · nonDerivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,865 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 12, 2024. Read SEC document |
| September 20, 2024 Filed Sep 20, 2024 20:24 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 2,354 | $4.78 | $11,252.12 |
DisclosureSEC source: 0001415889-24-023757 · form4-09202024_080939.xml · nonDerivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,365 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 19, 2024. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 20:20 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantCommon Stock | 2,011 | $4.98 | $10,014.78 |
DisclosureSEC source: 0001415889-24-017842 · form4-06212024_080631.xml · nonDerivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,011 F1 · kind: These shares were issued in accordance with the Issuer's Fifth Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 20, 2024. Read SEC document |
| June 06, 2024 Filed Jun 6, 2024 21:52 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 30,550 | $0.00 Strike: $4.65 | $0.00 |
DisclosureSEC source: 0001415889-24-015821 · form4-06062024_090608.xml · derivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,550 Underlying: Common Stock · 30,550 shares Expires 2034-06-05 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in full upon the earlier to occur of (i) June 6, 2025 or (ii) the Issuer's next annual meeting of stockholders, subject to the Reporting Person's continued service on such vesting date. Read SEC document |
| April 10, 2024 Filed Apr 12, 2024 21:29 UTC | Black Diamond Therapeutics, Inc. BDTX · Entity 6669 | GrantStock Option (Right to Buy) · Derivative | 61,100 | $0.00 Strike: $4.98 | $0.00 |
DisclosureSEC source: 0001415889-24-010770 · form4-04122024_090409.xml · derivative · entry 1 Campbell Shannon · CIK 0002018966 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,100 Underlying: Common Stock · 61,100 shares Expires 2034-04-09 F1 · derivative.exercise_date: The shares subject to this option shall vest and become exercisable in thirty-six (36) equal monthly installments, with the first installment vesting on May 10, 2024, subject to the Reporting Person's continued service on each such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.